The Effect of Combination of Mosapride and Dipeptidyl Peptidase-4 (DPP-4) Inhibitor on Plasma Concentration of Incretin Hormones

NCT02180334 Phase 4 COMPLETED

The aim of this study is to investigate the effects of combined administration of mosapride as modulator of gastrointestinal motility and DPP-4 inhibitor on secretion of gut hormone such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), and oral glucose tolerance. Additionally, change in lipid profile and insulin secretion will be also assessed.

Details

Lead sponsor	Seoul National University Hospital
Phase	Phase 4
Status	COMPLETED
Enrolment	12
Start date	2014-07
Completion	2015-04

Conditions

• Diabetes Mellitus, Type 2

Interventions

• Mosapride citrate
• Linagliptin
• Acetaminophen (paracetamol)

Primary outcomes

• Area under the curve (AUC) of plasma total GLP-1 levels — 0, 15, 30, 60, 90, 120, 150, 180 min after taking mixed meal (manufactured)
  AUC of plasma total GLP-1 levels during MMTT

Countries

South Korea